OZEMOS is a semaglutide-based product designed for weight loss and the treatment of type II diabetes mellitus.

OZEMOS is the trade name for Ozempic, a pharmaceutical product developed by Pharmacomlabs. The product has gained significant market traction due to its efficacy, safety profile, and user-friendly attributes.

Semaglutide reduces the concentration of glucose in the blood, reduces adipose tissue mass, and reduces energy intake. The mechanism of action addresses overall appetite reduction, including increased satiety signaling and attenuation of hunger signals, as well as improved control of food intake and decreased food cravings. Additionally, insulin resistance is diminished.

OZEMOS has been shown to have a positive effect on lipids, lower systolic BP, and reduce the risk of cardiovascular disease caused by excess weight.

The majority of the weight loss observed during semaglutide administration was attributed to adipose tissue reduction.

The half-life of semaglutide is approximately one week, which allows for a single subcutaneous injection of the drug per week throughout the duration of use.

The initial dose of OZEMOS is 0.25 mg once a week, which is gradually increased to 1 mg once a week. The duration of use can extend over several years, if necessary. Unlike steroids, the drug does not affect the production of sex hormones, making it suitable for use by both men and women. Additionally, there is no need for post-cycle therapy (PCT) following withdrawal of the drug.

Our OZEMOS is presented as a peptide dry powder that should be self-diluted with water for injection.

Our premium line of injectable products in ampules.